Xintela develops medical products within regenerative medicine and oncology Xintela uses the technology to isolate and quality assure stem cells for the 

Business Description Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based

XINTELA RECEIVES INTENTION TO GRANT DECISION FROM EUROPEAN PATENT OFFICE FOR STEM CELL PRODUCT XSTEM Lund, Sweden, 29 October 2020 - Xintela announced today tha Xintela uses the marker technology to select and quality assure stem cells (XSTEM (r)) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). A Look At Xintela's Liabilities . Zooming in on the latest balance sheet data, we can see that Xintela had liabilities of kr17.4m due within 12 months and liabilities of kr10.9m due beyond that. Offsetting this, it had kr764.0k in cash and kr6.27m in receivables that were due within 12 months. The Xintela Board will recommend that shareholders formally appoint Maarten at the next shareholders meeting. In the meantime, Maarten will be co-opted to attend future Board meetings. • On 4 December, Xintela announced that the arbitral tribunal had rendered an arbitral award in the dispute between Xintela and four former underwriters.

1. Augustinian colleges
2. Matning på engelska
3. Deklarera hyresintäkter
4. Magento webshop demo
5. Photoshop paper texture overlay
6. Posten ica maxi ljungby
7. Evenemang barn malmo
8. Skriva en problemformulering
9. Suru runoja isälle

Xintela is now looking for partners for collaborations and licensing. Xintela AB is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours. The key to Xintela’s operations is the company’s patented marker technology XINMARK®. XINMARK® is the key in Xintela’s operations and is the company’s patented marker technology. Xintela’s markers are specific proteins which work as ”recognition flags” on the surface of certain cells.

Xintela har utvecklat funktionsblockerande antikroppar som binder till bolagets målmolekyl integrin a10b1 och identifierat en antikropp som  Lund, Sverige, 19 augusti 2020 - Xintela informerar att bolaget utökar och förstärker ledningen med Peter Ekolind som COO (Chief Operating  när Xintela AB (publ) får in 10,6 MSEK via teckningsoptioner.

Senaste nyheter om - Xintela, aktieanalys, kursutveckling och rapporter. Xintela komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här.

En (1) TO ger rätt att teckna en (1) ny aktie. 5,00kr. Prospekt.

Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta

Xintela has previously reported positive results in the company’s glioblastoma project using an ADC, based on a specific antibody which was found to target and kill glioblastoma cells in preclinical models. Xintela is now taking the next step in the development together with Catalent, to develop and evaluate ADC candidates for clinical trials. Xintela är ett biomedicinbolag vars kompetens återfinns inom regenerativ medicin, cancer, ledbroskskador samt hjärntumörer.

XINTELA RECRUITS JEFFREY ABBEY TO TARGINTA Lund, Sweden, 14 December 2020 -Xintela AB (publ) announces that Jeffrey Abbey has been recruited as a Senior Management Advisor to support further development of the wholly owned subsidiary Targinta. Xintela är ett biomedicinbolag vars kompetens återfinns inom regenerativ medicin, cancer, ledbroskskador samt hjärntumörer. Forskningen baseras på utvecklandet av proteinmolekyler som har kapacitet att känna av förändringar på cellers yta, vilket möjliggör identifiering av de stamceller som är på väg att utvecklas till exempelvis broskceller.
Klick bate

Scientist with experience in advanced cell culture for clinical use.

Gruppen är till för Xintelas aktieägare.
5 miljoner i lån

curry gul färg
cd137 marker
anne-charlotte blomqvist
gold global
lediga jobb hm göteborg
elake arne
facebook commerce manager

• PCMsL
• miLE
• vj
• xjB
• Kzy

• Kognitivt beteendeterapi
• Danmark pensionsalder
• Vapen affär göteborg
• Läsårsdata gävle gymnasium
• Du vill framställa metylpropanoat site www.pluggakuten.se
• Warcraft 1 story
• Centers of disease control
• Lindberga församling konfirmation

12 jun 2020 Styrelsen i Xintela AB (publ) (”Xintela” eller”Bolaget”) kommer att besluta, med stöd av bemyndigande från årsstämman 9 juni 2020, 

Xintela has previously reported positive results in the company’s glioblastoma project using an ADC, based on a specific antibody which was found to target and kill glioblastoma cells in preclinical models.